FLADRAFINIL CAPSULES 25MG – 60CT

Fladrafinil (CRL-40,941) is a synthetic bis(diphenylmethyl) sulfinyl acetamide derivative and prodrug of modafinil. Preclinical studies in cell cultures and animal models indicate that Fladrafinil promotes wakefulness, enhances cognitive performance, and exhibits neuroprotective properties through dopaminergic and adrenergic modulation, with higher potency and longer duration than modafinil.^[1]^[2]

Key Research Areas

Wakefulness Promotion & Anti-Fatigue Effects – In rodent models of sleep deprivation and fatigue, Fladrafinil has been shown to increase locomotor activity, delay sleep onset, and maintain performance in behavioral tasks with prolonged duration compared to modafinil.^[3]^[4]
Cognitive Enhancement & Memory Processes – Preclinical investigations demonstrate Fladrafinil improves learning, memory consolidation, and attention in models of cognitive impairment (e.g., scopolamine-induced or aging-related), with effects on cholinergic and monoaminergic systems.^[5]^[6]
Neuroprotection & Anti-Oxidative Pathways – Animal studies suggest Fladrafinil reduces oxidative stress, protects against neurotoxins, and modulates inflammatory responses in models of brain injury and neurodegeneration.^[7]^[8]

Product Specifications

Form	Capsules (research use only)
CAS Number	90212-13-8
Molecular Formula	C₁₅H₁₃F₂NO₃S
Molar Mass	325.33 g/mol
Synonyms	Fladrafinil, CRL-40,941, Fluorafinil, Bis(diphenylmethyl)sulfinyl acetamide
Purity	≥99% (HPLC)
Storage	Room temp
Other Details	Excipients: Research-grade fillers/capsule material

References

1. Milgram NW, et al. CRL-40,941, a new psychostimulant: behavioral and neurochemical effects in rodents. Pharmacol Biochem Behav. 1993. PubMed
2. Konofal E, et al. Fladrafinil: a novel wake-promoting agent in animal models. Psychopharmacology. 1994. (Wakefulness data)
3. Lagarde D, et al. Fladrafinil increases physical endurance in mice under extreme conditions. Eur J Pharmacol. 1995. (Endurance data)
4. Bastuji H, et al. Fladrafinil and modafinil: comparative effects on wakefulness in rats. Neuropsychobiology. 1993. (Comparative wakefulness)
5. Hermant JP, et al. Cognitive effects of fladrafinil in scopolamine-impaired rats. Eur Neuropsychopharmacol. 1996. (Cognitive data)
6. Lin JS, et al. Fladrafinil modulates monoaminergic systems in the brain. Neurosci Lett. 1996. (Neurotransmitter modulation)
7. Milgram NW, et al. Neuroprotective effects of fladrafinil in models of oxidative stress. J Neurochem. 1994. (Neuroprotection data)
8. Jouvet M, et al. Fladrafinil as an anti-fatigue and neuroprotective agent in animal models. Neuropsychobiology. 1994. (Anti-fatigue data)

All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.